Noxopharm Ltd has released a press release.
Response to ASX Price Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- June 2022 Quarterly Activities Report and Appendix 4C
- March 2022 Quarterly Activities Report and Appendix 4C
- FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
- Orphan Drug Designation Granted to Noxopharm by US FDA
- First Patient Treated in CEP-2 Sarcoma Trial
Later from Noxopharm
- Novel Dual-cell Therapy Results in Pancreatic Cancer
- September 2022 Quarterly Activities Report and Appendix 4C
- NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
- DARRT-2 Trial Efficacy Phase to Commence
- December 2022 Quarterly Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm